Type 1 diabetes mellitus 12
Rare disease
No
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Type 1 diabetes mellitus 12
- type 1 diabetes mellitus 12
- IDDM12
- diabetes mellitus, insulin-dependent, type 12
- insulin-dependent diabetes mellitus 12
- diabetes mellitus, insulin-dependent, 12
- Severity
- Unknown
- MONDO ID
- MONDO:0011068
- Parent condition
- MONDO:0010255
Related records
Broader conditions (3)
- Diabetes mellitus, insulin-dependent, X-linked, susceptibility to
- Disease susceptibility
- Inherited disease susceptibility
Trials (76)
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
- A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
- A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
- A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
- A Phase II Study of CRT Combined With QL1706 in ESCC Patients
- A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
- A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
- A Study of a Personalized Neoantigen Cancer Vaccine
- A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
- A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
- A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
- A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma